ISSN: 1859 - 2872
Initial evaluation of the relationship between Cyfra 21-1 concentration and survival prognosis in patients with early-stage non-small cell lung cancer treated by stereotactic body radiation therapy
Main Article Content
Keywords
Abstract
Objective: To evaluate the relationship between Cyfra 21-1 concentration with prognostic in survival in early-stage NSCLC patients receiving SBRT. Subject and method: Prospective study, longitudinal follow-up of 32 patients with NSCLC stage T1-T2aN0M0 with peripheral lung tumors, who received SBRT and assessed survival from January 2015 to November 2021. The relationship with survival (PFS and OS) of clinical and paraclinical characteristics were analyzed by multivariate analysis. Result: Median age was 67 years, 35.5% of patients increased CEA and 22.6% patients increased Cyfra 21-1 before treatment. There was a positive, moderate, statistically significant correlation between Cyfra 21-1 concentration and tumor size, with correlation coefficient r = 0.4, p=0.024. Low pretreatment Cyfra 21-1 levels reduced the risk of progression disease by 44%, p=0.01. In contrast, high levels of Cyfra 21-1 after treatment increased the risk of progression disease by 1.6 times, p=0.016. Increased Cyfra 21-1 levels after SBRT 3 months increased the risk of death by 2.9 times with p=0.005. Conclusion: There was relationship between Cyfra 21-1 concentration before treatment with PFS, while Cyfra 21-1 after 3 months of treatment relate with both PFS and OS in patients with early-stage NSCLC treated by SBRT.
Article Details
References
2. Schneider BJ, Daly ME, Kennedy EB et al (2017) Stereotactic Body Radiation Therapy for Early-stage non-small cell lung cancer: American Society for Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol 36: 710-719.
3. Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic Body Radiation Therapy for Inoperable Early-Stage Lung Cancer. JAMA 303(11): 1070-1076.
4. Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a Prospective Phage II Trial of Medically Inoperable stage I non-small cell lung cancer patients treated with Stereotactic Body Radiation Therapy. J Clin Oncol 27: 3290-3296.
5. Saadeddin A (2012) Radiotherapy for NSCLC: Review of conventional and new treatment techniques. Journal of Infection and Public Health 5: 45-49.
6. Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16(6): 630-637.
7. Takeda K, Takanami K, Shirata Y et al (2017) Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy. Journal of Radiation Research 58(6): 862-869.
8. Horne ZD, Clump DA, Vargo JA et al (2014) Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiation Oncology 9: 41.
9. Shintani T, Matsuo Y, Iizuka Y et al (2017) Prognostic significance of serum CEA for non-small cell lung cancer patients receiving stereotactic body radiotherapy. Anticancer Research 37: 5161-5167.
10. Katsunari M, Shinichi S, Nariyasu N et al (2007) Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. European Journal of Cardio-thoracic Surgery 32: 435-439.
11. Muley T, Dienemann IH, and Ebert W (2004) CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Research 24: 1953-1956.
12. Chen ZQ, Huang LS, and Bo Zhu (2018) Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer Disease Markers, Article ID 9845123, 7 pages.
13. Suzuki H, Ishikawa S, Satoh H et al (2007) Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer. European Journal of Cardio-thoracic Surgery 32: 648-652.
14. Yu Z, Zhang G, Yang M et al (2017) Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis. Oncotarget 8(3): 4043-4050.
15. Park SY, Lee JG, Kim J et al (2013) Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer 79: 156-160.
Article Sidebar
